IAS 2007: Day Three & Conference Roundup
Joel Gallant, M.D., M.P.H., wraps up our daily recap series with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.
IAS 2007: Day Two
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
IAS 2007: Day One
Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
© 2018 Remedy Health Media, LLC. All Rights Reserved
TheBodyPRO: About TheBodyPRO | Contact TheBodyPRO | Content Policy | Advertise With Us
TheBodyPRO is a service of Remedy Health Media, 461 Fifth Avenue, 14th Floor, New York, NY 10017. TheBodyPRO and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.